Fatigue · women with usual‐type vulval intraepithelial neoplasia
Summary of findings for imiquimod probably leads to higher fatigue ‐ any grade compared with cidofovir (moderate certainty).
1 finding from 1 review
Headache · women with usual‐type vulval intraepithelial neoplasia
Summary of findings for imiquimod probably leads to higher headache ‐ any grade compared with cidofovir (moderate certainty).
1 finding from 1 review
Total serious adverse events · women with usual‐type vulval intraepithelial neoplasia
Summary of findings for imiquimod showed no clear difference in total serious adverse events compared with cidofovir (moderate certainty).
1 finding from 1 review
Treatment discontinuation · women with usual‐type vulval intraepithelial neoplasia
Summary of findings for imiquimod showed no clear difference in treatment discontinuation compared with cidofovir (moderate certainty).
1 finding from 1 review
Intervention not reported
Surgical excision versus laser vaporisationor other · women with usual‐type vulval intraepithelial neoplasia
1 finding from 1 review
Intervention not reported
Laser vaporisation versus CUSA · women with usual‐type vulval intraepithelial neoplasia
The intervention showed no clear difference in laser vaporisation versus CUSA (low certainty).
1 finding from 1 review
Intervention not reported
Photodynamic therapy versus laser vaporisationand surgical excision · women with usual‐type vulval intraepithelial neoplasia
1 finding from 1 review
Intervention not reported
LEEP versus laser vaporisation and surgical excision · women with usual‐type vulval intraepithelial neoplasia
1 finding from 1 review
Complete response · women with usual‐type vulval intraepithelial neoplasia
Summary of findings for imiquimod leads to higher response to treatment at 5 to 6 months ‐ complete response compared with placebo (high certainty).
2 findings from 1 review
Response to treatment at 12 months ‐ overall response · women with usual‐type vulval intraepithelial neoplasia
Summary of findings for imiquimod probably leads to higher response to treatment at 12 months ‐ overall response compared with placebo (moderate certainty).
1 finding from 1 review
Progression to vulval cancer at 12 months · women with usual‐type vulval intraepithelial neoplasia
Summary of findings for imiquimod showed no clear difference in progression to vulval cancer at 12 months compared with placebo (low certainty).
1 finding from 1 review
HPV DNA persistence · women with usual‐type vulval intraepithelial neoplasia
Summary of findings for imiquimod leads to lower HPV DNA persistence compared with placebo (high certainty).
1 finding from 1 review
Pain ‐ Any grade · women with usual‐type vulval intraepithelial neoplasia
Summary of findings for imiquimod leads to higher pain ‐ any grade compared with placebo (high certainty).
1 finding from 1 review
Dose reductions · women with usual‐type vulval intraepithelial neoplasia
Summary of findings for imiquimod leads to higher dose reductions compared with placebo (high certainty).
1 finding from 1 review
Response to treatment at 6 months ‐ overall response · women with usual‐type vulval intraepithelial neoplasia
Summary of findings for imiquimod showed no clear difference in response to treatment at 6 months ‐ overall response compared with cidofovir (moderate certainty).
1 finding from 1 review
Death by the end of · patients with rehabilitation needs
Day hospitals showed no clear difference in death by the end of compared with alternative care or no care (low certainty).
1 finding from 1 review
Deterioration in ADL in survivors · patients with rehabilitation needs
Day hospitals may leads to lower deterioration in ADL in survivors compared with no comprehensive care (low certainty).
1 finding from 1 review
Death by the end of · patients with rehabilitation needs
Day hospitals showed no clear difference in death by the end of compared with domiciliary care (low certainty).
1 finding from 1 review
Death or institutional care by the end of · patients with rehabilitation needs
Day hospitals showed no clear difference in death or institutional care by the end of compared with domiciliary care (low certainty).
1 finding from 1 review
Death or deterioration in ADL · patients with rehabilitation needs
Day hospitals showed no clear difference in death or deterioration in ADL compared with domiciliary care (low certainty).
1 finding from 1 review